{"title":"源自患者的肿瘤器官组织:肿瘤学临床前研究和精准医疗的新途径。","authors":"Lucie Thorel, Marion Perréard, Romane Florent, Jordane Divoux, Sophia Coffy, Audrey Vincent, Cédric Gaggioli, Géraldine Guasch, Xavier Gidrol, Louis-Bastien Weiswald, Laurent Poulain","doi":"10.1038/s12276-024-01272-5","DOIUrl":null,"url":null,"abstract":"Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has broadened the repertoire of preclinical models and progressively revolutionized three-dimensional cell culture in oncology. PDTO can be grown from patient tumor samples with high efficiency and faithfully recapitulates the histological and molecular characteristics of the original tumor. Therefore, PDTOs can serve as invaluable tools in oncology research, and their translation to clinical practice is exciting for the future of precision medicine in oncology. In this review, we provide an overview of methods for establishing PDTOs and their various applications in cancer research, starting with basic research and ending with the identification of new targets and preclinical validation of new anticancer compounds and precision medicine. Finally, we highlight the challenges associated with the clinical implementation of PDTO, such as its representativeness, success rate, assay speed, and lack of a tumor microenvironment. Technological developments and autologous cocultures of PDTOs and stromal cells are currently ongoing to meet these challenges and optimally exploit the full potential of these models. The use of PDTOs as standard tools in clinical oncology could lead to a new era of precision oncology in the coming decade. The shift from 2D to 3D cell cultures has greatly improved cancer research, providing a more realistic model of tumors. Patient-Derived Tumor Organoids (PDTOs) have become a key tool in cancer research, allowing scientists to grow efficiently tumor cells from patient samples in a 3D environment that closely mirrors the original tumor. PDTOs are a major step forward in cancer research, bridging the gap between traditional cell cultures and clinical realities, with the potential for successful clinical applications despite some challenges that could be overcome by technological developments. Thus, they offer a promising platform for understanding cancer, testing drug responses, and developing personalized treatments, with the potential to greatly impact future patient care. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":null,"pages":null},"PeriodicalIF":9.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297165/pdf/","citationCount":"0","resultStr":"{\"title\":\"Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology\",\"authors\":\"Lucie Thorel, Marion Perréard, Romane Florent, Jordane Divoux, Sophia Coffy, Audrey Vincent, Cédric Gaggioli, Géraldine Guasch, Xavier Gidrol, Louis-Bastien Weiswald, Laurent Poulain\",\"doi\":\"10.1038/s12276-024-01272-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has broadened the repertoire of preclinical models and progressively revolutionized three-dimensional cell culture in oncology. PDTO can be grown from patient tumor samples with high efficiency and faithfully recapitulates the histological and molecular characteristics of the original tumor. Therefore, PDTOs can serve as invaluable tools in oncology research, and their translation to clinical practice is exciting for the future of precision medicine in oncology. In this review, we provide an overview of methods for establishing PDTOs and their various applications in cancer research, starting with basic research and ending with the identification of new targets and preclinical validation of new anticancer compounds and precision medicine. Finally, we highlight the challenges associated with the clinical implementation of PDTO, such as its representativeness, success rate, assay speed, and lack of a tumor microenvironment. Technological developments and autologous cocultures of PDTOs and stromal cells are currently ongoing to meet these challenges and optimally exploit the full potential of these models. The use of PDTOs as standard tools in clinical oncology could lead to a new era of precision oncology in the coming decade. The shift from 2D to 3D cell cultures has greatly improved cancer research, providing a more realistic model of tumors. Patient-Derived Tumor Organoids (PDTOs) have become a key tool in cancer research, allowing scientists to grow efficiently tumor cells from patient samples in a 3D environment that closely mirrors the original tumor. PDTOs are a major step forward in cancer research, bridging the gap between traditional cell cultures and clinical realities, with the potential for successful clinical applications despite some challenges that could be overcome by technological developments. Thus, they offer a promising platform for understanding cancer, testing drug responses, and developing personalized treatments, with the potential to greatly impact future patient care. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.\",\"PeriodicalId\":50466,\"journal\":{\"name\":\"Experimental and Molecular Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":9.5000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297165/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and Molecular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s12276-024-01272-5\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s12276-024-01272-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology
Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has broadened the repertoire of preclinical models and progressively revolutionized three-dimensional cell culture in oncology. PDTO can be grown from patient tumor samples with high efficiency and faithfully recapitulates the histological and molecular characteristics of the original tumor. Therefore, PDTOs can serve as invaluable tools in oncology research, and their translation to clinical practice is exciting for the future of precision medicine in oncology. In this review, we provide an overview of methods for establishing PDTOs and their various applications in cancer research, starting with basic research and ending with the identification of new targets and preclinical validation of new anticancer compounds and precision medicine. Finally, we highlight the challenges associated with the clinical implementation of PDTO, such as its representativeness, success rate, assay speed, and lack of a tumor microenvironment. Technological developments and autologous cocultures of PDTOs and stromal cells are currently ongoing to meet these challenges and optimally exploit the full potential of these models. The use of PDTOs as standard tools in clinical oncology could lead to a new era of precision oncology in the coming decade. The shift from 2D to 3D cell cultures has greatly improved cancer research, providing a more realistic model of tumors. Patient-Derived Tumor Organoids (PDTOs) have become a key tool in cancer research, allowing scientists to grow efficiently tumor cells from patient samples in a 3D environment that closely mirrors the original tumor. PDTOs are a major step forward in cancer research, bridging the gap between traditional cell cultures and clinical realities, with the potential for successful clinical applications despite some challenges that could be overcome by technological developments. Thus, they offer a promising platform for understanding cancer, testing drug responses, and developing personalized treatments, with the potential to greatly impact future patient care. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
期刊介绍:
Experimental & Molecular Medicine (EMM) stands as Korea's pioneering biochemistry journal, established in 1964 and rejuvenated in 1996 as an Open Access, fully peer-reviewed international journal. Dedicated to advancing translational research and showcasing recent breakthroughs in the biomedical realm, EMM invites submissions encompassing genetic, molecular, and cellular studies of human physiology and diseases. Emphasizing the correlation between experimental and translational research and enhanced clinical benefits, the journal actively encourages contributions employing specific molecular tools. Welcoming studies that bridge basic discoveries with clinical relevance, alongside articles demonstrating clear in vivo significance and novelty, Experimental & Molecular Medicine proudly serves as an open-access, online-only repository of cutting-edge medical research.